Undifferentiated Ovarian Carcinoma Completed Phase 2 Trials for Everolimus (DB01590)

IndicationStatusPhase
DBCOND0028876 (Undifferentiated Ovarian Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02283658Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerTreatment